← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Novartis NVS $279B	940	+21	+2%	$23.1B
2	2 Charles River Laboratories CRL $14.4B	259	+7	+3%	$3.71B
3	3 DELISTED bluebird bio BLUE	210	+41	+24%	$3.81B
4	4 DELISTED SANGAMO THERAPEUTICS INC SGMO	171	+13	+8%	$827M
5	5 PTC Therapeutics PTCT $4.98B	157	+25	+19%	$1.92B
6	6 Precigen PGEN $2.64B	154	+46	+43%	$4.29B
7	ISEE 7 DELISTED IVERIC bio, Inc. Common Stock ISEE	129	+13	+11%	$1.4B
8	8 Ultragenyx Pharmaceutical RARE $1.47B	126	+26	+26%	$1.96B
9	9 DELISTED CATALENT, INC. CTLT	118	+24	+26%	$3.72B
10	10 Sarepta Therapeutics SRPT $1.78B	114	-6	-5%	$321M
11	11 DELISTED Adverum Biotechnologies ADVM	113	+29	+35%	$644M
12	BLCM 12 DELISTED Bellicum Pharmaceuticals, Inc. BLCM	71	+16	+29%	$340M
13	13 Lineage Cell Therapeutics LCTX $232M	69	+10	+17%	$152M
14	AGTC 14 DELISTED Applied Genetic Technologies Corporation AGTC	59	+11	+23%	$178M
15	ATHX 15 DELISTED Athersys, Inc. Common Stock ATHX	53	+6	+13%	$26.2M
16	16 Atara Biotherapeutics ATRA $96M	53	+14	+36%	$462M
17	17 DELISTED Carisma Therapeutics CARM	51	+10	+24%	$119M
18	18 Fortress Biotech FBIO $63.4M	49	+13	+36%	$33.7M
19	19 Cellectis CLLS $113M	44	+44	–	$213M
20	20 uniQure QURE $1.45B	41	+13	+46%	$120M
21	21 Opus Genetics IRD $341M	35	-3	-8%	$5.94M
22	22 Vericel Corp VCEL $2.06B	35	0	0%	$40.1M
23	23 Pluri PLUR $11.7M	32	+3	+10%	$4.27M
24	24 Imunon IMNN $5.84M	26	-7	-21%	$7.42M
25	25 Fate Therapeutics FATE $232M	25	+2	+9%	$51.9M